The leucine 211 3 phenylalanine (L211F) and leucine 211 3 tyrosine (L211Y) mutant forms of cytochrome P450 3A4 have been generated by site-directed mutagenesis and expressed functionally in Escherichia coli. Substrate binding affinities (S 50 values) for testosterone and 7-benzyloxy-4-trifluoromethylcoumarin (BFC) were similar for the mutants and wild-type CYP3A4 (49 and 21 M for L211F, 35 and 20 M for L211Y, and 33 and 20 M for the wild type, respectively). For erythromycin, however, the K m values determined for the L211F and L211Y mutants were 2.4-and 10.5-fold higher than for the wild type. Furthermore, IC 50 values for the inhibition of testosterone 6␤-hydroxylation by erythromycin and troleandomycin for L211F were 2.4-and 3.7-fold higher, and those for L211Y were 3.4-and 9.2-fold higher than those measured for the wild type. Conversely, small inhibitors, such as diazepam, exhibited no significant difference in IC 50 values between the wild type and the L211F and L211Y mutants. It is proposed that large substrates bound in the catalytic center of CYP3A4 with molecular volumes greater than ϳ600 Å 3 were less well accommodated in the altered active sites, resulting in lower association energies and increased IC 50 values.
Cytochrome P450 3A4 (CYP3A4) is known to metabolize a very large variety of compounds varying in molecular weight from lidocaine (mol. wt. ϭ 234) to cyclosporin A (mol. wt. ϭ 1203). It is thought that this is achieved by having a large, hydrophobic active site, which can accommodate a diverse range of compounds. As a result, CYP3A4 binding interactions are dominated by the lipophilicity of the drug molecule involved, there being a strong correlation between the octanol partition coefficient (log D 7.4 ) and CYP3A4 K i (Ishigami et al., 2001; Riley et al., 2001 ). In the drug development process, potential drug-drug interactions or high oxidative clearance due to interactions with some cytochromes P450 can be ameliorated by minor chemical modifications. For instance, when the carbon chain length of imipramine was reduced by one methylene unit, the inhibition of CYP2D6 bufuralol hydroxylation was reduced 27-fold (Halliday et al., 1997) . Such changes are unlikely to attenuate CYP3A4 substrate binding or metabolism.
The most distant amino acids from the catalytic center of CYP3A4 that have a role in substrate binding are leucine 210, leucine 211, and aspartic acid 214 Halpert, 1997, 1998) . Modeling and amino acid alignment studies have proposed that these amino acids occupy positions in the F-helix, remote from the heme iron of the CYP3A4 active site (Szklarz and Halpert, 1997) . Mutagenesis studies have demonstrated that replacement of leucine 210 or leucine 211 with alanine reduced, but did not abolish, the activation effect of ␣-naphthoflavone on progesterone and testosterone hydroxylase activities (Harlow and Halpert, 1997) . Further mutagenesis studies, in which leucine 211 was replaced with phenylalanine and aspartic acid 214 replaced with glutamic acid, displayed hyperbolic rather than sigmoidal substrate-saturation kinetics (Harlow and Halpert, 1998) . From these studies, it has been proposed that the L211F mutation constricted the active site, limiting the simultaneous binding of more than one substrate molecule to the CYP3A4 active site as required for allosteric enhancement. This study has used the L211F and L211Y mutant forms of CYP3A4 to examine substrate occupancy of the CYP3A4 active site and shows that the CYP3A4 active site can be constricted to a volume of approximately 600 Å 3 without adversely affecting metabolic activity toward testosterone, BFC, 1 or diazepam.
Materials and Methods
All reagents and fine chemicals were obtained from Sigma-Aldrich (Poole, Dorset, UK), with the following exceptions: isopropyl ␤-D-thiogalactoside (Invitrogen, Carlsbad, CA); aprotinin, ampicillin, and leupeptin (Roche Applied Science, Indianapolis, IN); N-methyl-( 14 C)-erythromycin (PerkinElmer Life Sciences, Boston, MA); and 7-benzyloxy-4-trifluoromethylcoumarin and 7-hydroxy-4-trifluoromethylcoumarin (GENTEST, Woburn, MA). Enzymes for DNA manipulation were obtained from Promega (Madison, WI).
Expression of CYP3A4 and Cytochrome P450 Reductase in Escherichia coli. Mutagenesis reactions were performed following the single-stranded method of Kunkel (1985) . The reverse complementary primers 5Ј-AAAAT-CAAATCTAAAGAGCTTCTTGGTGTTTTC-3Ј and 5Ј-AAAATCAAATCT-GTAGAGCTTCTTGGTGTTTTC-3Ј introduced the L211F and L211Y mutations, respectively. Transformant clones were checked for mutagenesis by manual dideoxy chain termination sequencing using the T7 sequenase kit (Amersham Biosciences, Piscataway, NJ). Protein expression and quantitation experiments were carried out as described previously (Fowler et al., 2000) . Briefly, expression experiments were carried out as described by Blake et al. (1996) and Pritchard et al. (1997 Pritchard et al. ( , 1998 , using the expression vectors pB35 and pB212. Protein yields were in the range of 50 to 200 nmol of P450 per liter of bacterial cell culture. E. coli membranes containing CYP3A4 and human cytochrome P450 reductase were prepared by the method of Blake et al. (1996) and resuspended in detergent-free 1ϫ TSE buffer (50 mM Tris acetate, pH 7.6, 250 mM sucrose, and 0.25 mM EDTA). The cytochrome c (horse heart; Sigma) reductase activity was determined spectroscopically by the method of Vermilion and Coon (1974) , monitoring at 550 nm with an extinction coefficient change of 21,400 M Ϫ1 cm
Ϫ1
. This indicated P450 reductase concentrations to be greater than three times that of CYP3A4. All experiments were carried out using E. coli membrane suspensions in aqueous buffers in the absence of lipid, detergent, or cytochrome b 5 and without further purification or reconstitution steps. Turnover rates measured in this study were generally lower than those reported by other laboratories using insect cell-expressed or purified and reconstituted CYP3A4, due to the nonoptimized nature of the E. coli membrane preparations.
Diazepam, Testosterone, Erythromycin, and BFC Metabolism. Diazepam, testosterone, and erythromycin substrate saturation kinetics and inhibition experiments were carried out as described previously (Fowler et al., 2000) . BFC kinetics were determined as follows: incubations containing BFC in methanol (1% v/v), CYP3A4 (150 pmol), and NADPH (1 mM final) were made up with deionized water and 2ϫ HEPES buffer (final concentrations 50 mM HEPES/20 mM MgCl 2 ; pH 7.4) to total incubation volumes of 200 l. Enzyme and substrate were preincubated for 5 min before initiation by addition of NADPH. Generation of the fluorescent metabolite, 7-hydroxy-4-trifluoromethylcoumarin, was measured over 30 min using a Spectrofluor Plus (TECAN, Durham, NC) instrument equipped with 405-nm excitation and 535-nm emission filters. Initial metabolism rates (typically the mean rate over the first 6 to 9 min was used, where the reaction rate was linear) were calibrated against the authentic metabolite standards.
Inhibition assay incubations contained 20 M BFC, 150 pmol of P450, and 1 mM NADPH in 50 mM HEPES/20 mM MgCl 2 buffer, to which test compound in acetonitrile/pure acetonitrile (2% v/v) was added. Incubations were preincubated for 5 min at 37°C before initiation by NADPH addition. Presence of the additional 2% v/v acetonitrile reduced turnover rates by ϳ10%, similar to the effects of acetonitrile observed for CYP3A4 by others (Chauret et al., 1998; Busby et al., 1999) . Fluorescent product generation was measured as above.
Data Treatment. Nonlinear regression analysis was performed using the program Origin 5.0 (MicroCal Software, Inc., Northampton, MA) with either the Michaelis-Menten or Hill equations fitted to the substrate saturation data, as appropriate to the enzyme/substrate combination. A simple inhibition effect model was fitted to the inhibition data. K i values were estimated using the relationship K i ϭ IC 50 /(1 ϩ [S/S 50 ]), where S was the substrate concentration used in the assay, S 50 was the half-saturation substrate concentration, and IC 50 was the inhibitor concentration, which resulted in 50% inhibition of enzyme activity. More complex estimates of K i to take account of the sigmoidal nature of some of the substrate-saturation profiles, have not been used in this analysis (Leff and Dougall, 1993) . Molecular volumes were calculated using Cerius II (Advanced Visual Systems and Molecular Simulations, Waltham, MA) with an initial geometry optimization followed by calculation of the Van der Waals volume.
Results
Enzyme Kinetics. Kinetic parameters for testosterone 6␤-hydroxylase, diazepam N-demethylase, diazepam 3-hydroxylase, erythromycin N-demethylase, and BFC debenzylase activities were determined and are shown in Fig. 1 and Table 1 . S 50 values for all three enzyme forms were similar for testosterone and BFC, whereas the S 50 values for erythromycin of the L211F and L211Y mutants were 2.4-and 10-fold higher than that of the wild type, respectively. The wild type and L211F showed similar S 50 values for diazepam, whereas the values for the L211Y mutant were unexpectedly lower. For the three smaller substrates, testosterone, diazepam, and BFC, the L211F mutant displayed the highest V max values, followed by the wild type. The L211Y mutant showed the lowest V max values. For erythromycin, this order was partially reversed, with the wild type exhibiting the highest V max followed by the L211F and L211Y mutants, respectively.
Inhibition. Figure 2 shows the inhibition profiles generated using diazepam, bromocriptine, erythromycin, and troleandomycin. The K i values estimated from these inhibition profiles are shown in Tables 2  and 3 for inhibition of testosterone 6␤-hydroxylase and BFC debenzylase activities, respectively. K i values estimated using the two different substrates for the three different enzyme forms were generally in agreement. However, differences were seen between the values estimated for progesterone and vinblastine between the two substrate probes. This may have been a reflection of the difference in character of the substrate probes used. In general, BFC showed greater sensitivity than testosterone to the effect of the site-directed mutations on inhibitor K i values, compared with the wild type.
In Tables 2 and 3 , the competitive substrates have been listed in order of molecular weight. It can be seen that, for the smaller competitive inhibitors, diazepam, nifedipine, diltiazem, progesterone, haloperidol, verapamil, and bromocriptine, the K i values for the L211F and L211Y mutants were within 2.5-fold of the wild type both for testosterone and BFC inhibition. The leucine 211 mutant enzyme K i values for both substrates were significantly greater than those of the wild type for erythromycin, vinblastine, troleandomycin, and cyclosporin A.
Correlation (Riley et al., 2001) in Fig. 5 . All three enzyme forms showed a high degree of correlation between the K i values estimated in these studies and the octanol partition coefficients.
Discussion
In this study, the effect of CYP3A4 amino acid substitutions at positions in the active site thought to be remote from the heme have been investigated. A variety of substrate probes and inhibitors have been used to characterize the effects of the L211F and L211Y mutations and ascertain whether the effects seen were general or substratedependent.
The less conservative amino acid substitution, leucine 3 tyrosine, had a significant effect in attenuating overall enzyme activity, whereas the L211F mutation generated an enzyme form at least as active as the wild type in carrying out a variety of CYP3A4-mediated biotransformations. These findings were consistent with those of Khan and Halpert (2000) , who found that the L211F and wild type had similar 7-hexoxycoumarin metabolism activities whereas the L211Y mutant activity was about 3-fold lower.
Of the reactions studied, only erythromycin showed true MichaelisMenten hyperbolic kinetics, indicating that although it was possible for more than one molecule of testosterone, diazepam, or BFC to bind to the active site simultaneously, only a single molecule of erythromycin was probably accommodated. Better fitting of the substrate saturation profiles for testosterone, BFC, and diazepam was achieved by introducing an element of sigmoidicity in all three enzyme forms. The Hill coefficients for the L211F and L211Y mutants were lower than those determined for the wild type, as might be expected from the results of Harlow and Halpert (1998) who demonstrated that the L211F mutation reduced the sigmoidicity of steroid hydroxylase kinetics for CYP3A4. These studies have demonstrated the reduction of sigmoidicity for the kinetics of CYP3A4 leucine 211 mutants applied to benzodiazepines and 7-hydroxycoumarin derivatives as well as steroids.
As an indirect measure of active site binding/competition during catalysis, inhibition of metabolism has been used as a tool to investigate changes in active site association. Testosterone and BFC were selected as chemically dissimilar substrates that showed very similar S 50 values for the wild type, L211F, and L211Y mutants and had S 50 values well below the aqueous substrate solubility limits.
The strong relationship between estimated K i and measured log D 7.4 (Fig. 5 ) for all three enzyme forms indicated that lipophilicity was still the dominant factor in determining active site association of a variety of diverse molecules. In these correlations, the L211Y mutant exhibited the lowest correlation coefficients (r 2 ϭ 0.85 for BFC; r 2 ϭ 0.84 for testosterone). The hydroxyl group of the tyrosine introduced in the L211Y mutant could interact with the inhibitor molecules differentially, decreasing the r 2 of the lipophilicity-IC 50 correlation. However, the major reason for the reduction in r 2 value was the increase in erythromycin and troleandomycin IC 50 values relative to the other inhibitors tested. Despite the increase in erythromycin and troleandomycin IC 50 values, the correlation with lipophilicity was strongest for the L211F mutant (r 2 ϭ 0.97 for both BFC and testosterone). Introduction of a phenylalanine residue at position 211 thus appeared to enhance the dependence of compound binding to CYP3A4 of log D 7.4 .
The relationship between molecular size and the difference in K i values between the wild type and the L211F and L211Y mutants is represented graphically in Fig. 3 . Here the effect of the leucine 3 phenylalanine/tyrosine substitutions on enzyme inhibition by large molecules was dramatic (see Fig. 4 for structures of competitive dmd.aspetjournals.org inhibitors tested in this study). For both the L211F and L211Y mutants, vinblastine, troleandomycin, and to a lesser extent, erythromycin were above the threshold size where K i values are many times greater than determined for the wild type. These effects were more pronounced for the L211Y mutant, where the estimated K i value for troleandomycin inhibition of BFC metabolism was 43-fold higher than the wild type. The molecular weight at which these effects became apparent was somewhere between bromocriptine (mol. wt. ϭ 657; molecular volume ϭ 551 Å 3 ) and erythromycin (mol. wt. ϭ 734; molecular volume ϭ 681 Å 3 ). Thus, the threshold molecular volume at which differential inhibition was seen was ϳ600 Å 3 . On these plots, cyclosporin A was a notable outlier, having a very large molecular volume but not giving the fold increase in L211F and L211Y IC 50 values expected for such a large molecule. As the largest increases in IC 50 for the L211F mutant were 9-to 13-fold, and these changes were comparable to those observed for cyclosporin A, it could be inferred that there was a maximum K i increase, which could be generated by the L211F mutation, of around 10-fold. However, for the L211Y mutant, vinblastine and troleandomycin showed (for testosterone and BFC, respectively) almost double the fold increase in K i values (relative to wild-type CYP3A4) to those generated by cyclosporin A. Therefore, for the L211Y mutant at least, cyclosporin A did not elicit the greatest increase in K i of any test compound despite being the largest compound used in this study. Cyclosporin A can be metabolized at several different positions by CYP3A4 (Kronbach et al., 1988) , and it has been postulated that cyclosporin A may be 3 ) for inhibition of testosterone 6␤-hydroxylase activity (A and B) and BFC debenzylase activity (C and D) . values for a compound were indicative of the volume of compound inserted into the enzyme active sites, just over half of the cyclosporin A molecule could be expected to be bound within the CYP3A4 active site cavity. Such a hypothesis is, however, only likely to be proven by the generation of a CYP3A4 crystal structure in which cyclosporin A is bound.
In conclusion, this study has demonstrated that the L211F and L211Y mutations not only reduced the sigmoidal character of testosterone and BFC substrate saturation kinetics, but also that the mutations differentially affected the inhibitors in a molecular volume-dependent manner. The competitive inhibition of testosterone and BFC oxidation by compounds with molecular volumes less than ϳ600 Å 3 was unaffected, or only marginally affected, by the substitution of leucine 211 with phenylalanine or tyrosine. Changes in inhibition potencies of up to 43-fold were observed for compounds of molecular volume greater than ϳ600 Å 3 in the L211F and L211Y mutants.
It is concluded that these mutations have reduced the CYP3A4 active site volume in a region remote from the catalytic center to create enzymes with effective active site volumes of ϳ600 Å 3 . The ability of vinblastine, troleandomycin, and cyclosporin A to bind to the smaller active site of the mutants was reduced but not abolished. Similarly, the allosteric character of testosterone and BFC substratesaturation kinetics were reduced, but not abolished, by these mutations. It is likely that the CYP3A4 active site is flexible enough to accommodate substrate molecules with molecular volumes up to 750 Å 3 or simultaneous binding of more than one smaller molecule. However, in the L211F and L211Y mutants, the amount of strain placed upon the enzyme when accommodating compounds of molecular volume Ͼ600 Å 3 may have been increased, making such interactions less favorable.
